Page 5 - The Hemophilia Times 2.0_Neat

Yes. It is HAVEN 2.

TRIAL DESIGN It is the largest ongoing
single-arm, multicentre,

TREATMENT IN PRIOR 24 WEEKS AT LEAST 52 WEEKS’ TREATMENT open-label, phase III study
Compared with BPA
on-demand, HEMLIBRA BPA (n=23) switched to HEMLIBRA prophylaxis (n=23) in paediatricpatients
62.9 % delivered unprecedented Intra-patient analysis: n=13 with FVIII inhibitors

OF PATIENTS HAD ZERO TREATED bleed protection Interim efficacy analyses based on median duration of 38.1 (range 12.7-41.6) weeks.
BLEEDS WITH HEMLIBRA PROPHYLAXIS

Is it?
What were the end results, Any study for
compared with BPA on-demand pediatric patients too?

Compared with BPA
prior prophylaxis too, In paediatric patients,
HEMLIBRA delivered HEMLIBRA resulted
unprecedented bleed in substantial

70.8 % protection 87 % bleed protection

OF PATIENTS HAD ZERO TREATED OF PAEDIATRIC PATIENTS HAD ZERO TREATED
BLEEDS WITH HEMLIBRA PROPHYLAXIS BLEEDS WITH HEMLIBRA PROPHYLAXIS
And what about BPA
prior prophylaxis?

What are the results of the study?

For internal use only For internal use only